Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

The competition for treatments in the weight-loss market is heating up. Amgen is currently working on a promising anti-obesity medicine.

Amgen Is Working On a Wegovy Competitor -- What It Means for Investors

Apple

Amazon

Boeing

Goldman Sachs

Dow Jones outperforms at the start of May as the market rally broadens and reconstruction of the index finally pays off.

5 Stocks Driving Dow's Market-Beating Performance

THOUSAND OAKS, Calif. , May 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m.

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

Altimmune

AstraZeneca

Structure Therapeutics Inc

Merck

Pfizer

Viking Therapeutics

Investors are well aware of the explosive growth potential in weight loss drug stocks. That growth began last year with Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ).

7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025

First Solar

General Motors

During this earnings season, Wall Street investors have been paying attention to stocks generating buzz in different sectors. Diversifying investments across the 11 sectors within the S&P 500 index could help weather short-term market volatility.

Sector Superstars: 3 Stocks Generating the Most Buzz on Wall Street

Amgen stock (NASDAQ NASDAQ : AMGN) has seen a solid 9% rise in a week, outperforming the broader S&P500 index, up 1.5%. The recent rise can be attributed to the progress with its weight-loss drug — MariTide and its upbeat Q1 results reported last week.

Will Amgen Stock Continue To See Higher Levels Driven By Its Obesity Injection?

Chevron

PepsiCo

Picking income stocks can be challenging. Some companies pay dividends only to cut them in the future, and others are more focused on stock buybacks instead of dividends.

3 Tried and True Dividend Stocks to Buy for Your Portfolio

Eli Lilly

Novo Nordisk

Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

Caterpillar

Check out these Dow Jones stocks for your May 2024 watch list.

Best Dow Jones Stocks To Buy Right Now? 2 For Your Watch List

Amgen's shares surged after management's earnings call comments about the phase 2 trial of obesity candidate MariTide. These comments and previous phase 2 data point to the increasing possibility of Amgen becoming a real contender in the rapidly expanding obesity market. MariTide would be a good start for Amgen but additional solutions may be required to remain relevant in the obesity market in the long run.

Amgen Could Become A Real Contender In The Obesity Market

On the earnings front, the biotech beat estimates with non-GAAP EPS of $3.96 vs. the expected $3.88.

Amgen Delivers a Q1 Earnings Beat

The pharmaceutical sector mainstay published its first-quarter results. These beat on both the top and bottom lines.

Why Amgen Stock Zoomed Nearly 12% Higher Today

Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.

Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update

Amgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.

Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide

Amgen (NASDAQ: AMGN ) stock is trending and up about 12% as of this writing. The shares are rallying after the drugmaker's CEO said he was encouraged by preliminary data on Amgen's weight-loss drug.

AMGN Stock Alert: Is Amgen the Next Hot Weight-Loss Drug Company?

Amgen Inc (NASDAQ:AMGN, ETR:AMG) shares gained almost 13% at about $314 in early trade on Friday after the drugmaker said it was “very encouraged” by interim trial data for its experimental weight loss drug MariTide. If approved, MariTide would compete with drugs such as Novo Nordisk (NYSE:NVO)'s Wegovy and Eli Lilly and Co (NYSE:LLY)'s Zepbound, which currently dominate the weight loss market.

Amgen shares soar on obesity drug optimism

Fueled by upbeat management comments on an experimental obesity treatment, Amgen's stock jumped more than 12% early Friday — and analysts see more gains ahead as the company maps out late-stage trials for the drug.

Amgen's obesity-drug stock surge still in ‘early innings,' analysts say

U.S. stock futures were solidly higher Friday morning as investors digested a slew of earnings reports and awaited the monthly U.S. employment report.

Dow Jones Today: Stock Futures Higher Ahead of Jobs Data; Apple, Amgen Surging

Shares in Danish drugmaker Novo Nordisk dropped as much as 5.3% on Friday, set for their biggest one-day fall since August 2022, after rival Amgen said it was encouraged by interim trial data on its experimental obesity drug.

Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data

U.S. drugmaker Amgen's shares jumped 13% to $316.26 premarket on Friday as the company teased encouraging data for its experimental obesity drug, igniting investor hopes but leaving Wall Street frustrated over a lack of details.

Amgen shares jump after teasing 'encouraging' weight loss data

The company is trying to carve a niche in a rapidly growing obesity-drug market that's currently dominated by Eli Lilly and Novo Nordisk.

Amgen Stock Jumps on Obesity Drug Optimism. What Comes Next.

Amgen (AMGN) shares surged more than 14% in extended-hours trading on Thursday after the biopharmaceutical giant posted quarterly earnings that came in ahead of Wall Street expectations and provided a positive update about trials of its injectable weight-loss drug MariTide.

Amgen Stock Surges After Q1 Earnings Beat, 'Encouraging' Weight-Loss Drug Update

Amgen, Inc. (NASDAQ:AMGN ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President James Bradner - EVP, Research and Development & Chief Scientific Officer Vikram Karnani - EVP & President, Global Commercial Operations & Medical Affairs (Rare Disease) Murdo Gordon - EVP, Global Commercial Operations Peter Griffith - EVP & CFO Conference Call Participants Salveen Richter - Goldman Sachs Group Michael Yee - Jefferies Terence Flynn - Morgan Stanley Srikripa Devarakonda - Truist Securities Timothy Anderson - Wolfe Research Yaron Werber - TD Cowen Umer Raffat - Evercore ISI Jay Olson - Oppenheimer Christopher Schott - JPMorgan Chase & Co. Geoffrey Meacham - Bank of America Merrill Lynch Gary Nachman - Raymond James & Associates Mohit Bansal - Wells Fargo Securities Michael Schmidt - Guggenheim Securities James Shin - Deutsche Bank Gregory Renza - RBC Capital Markets Evan Seigerman - BMO Capital Markets Operator My name is Julianne, and I will be your conference facilitator today for Amgen's First Quarter 2024 Financial Results Conference Call. [Operator Instructions].

Amgen, Inc. (AMGN) Q1 2024 Earnings Call Transcript

The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Amgen (AMGN) Q1 Earnings

Shares of Amgen Inc. rallied more than 11% in the extended session Thursday after the drugmaker posted adjusted earnings above expectations and said that plans for further trials for its weight-loss drug are proceeding apace.

News for Amgen Stock (AMGN)